Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
FOXO4-DRI vs SS-31 (Elamipretide)
An educational, source-based comparison of FOXO4-DRI and SS-31 (Elamipretide) — how each peptide works, what it's researched for, and what to know before going deeper.
A D-retro-inverso peptide that disrupts the FOXO4-p53 interaction inside senescent cells, selectively triggering their apoptosis while sparing healthy cells in preclinical models.
- Senescent cell clearance
- Tissue function in aged mice
- Fibrotic disease models
- • No human trials; safety and pharmacokinetics in humans unknown.
- • Not FDA-approved.
Cardiolipin-targeting peptide studied for mitochondrial dysfunction.
A tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure, preserving electron transport efficiency, and reducing reactive oxygen species production.
- Heart failure with preserved ejection fraction
- Primary mitochondrial myopathy
- Age-related muscle dysfunction
- Dry AMD (ophthalmology)
- • Investigational; not FDA-approved.
- • Injection-site reactions are common in trials.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| FOXO4-DRI | Targeted apoptosis of senescent cells restores tissue homeostasis | Cell | 2017 | Foundational paper establishing FOXO4-DRI as a selective senolytic in mice. |
| SS-31 (Elamipretide) | Elamipretide in primary mitochondrial myopathy (MMPOWER-3) | Neurology | 2020 | Did not meet primary endpoints but showed signals in subgroup analyses. |
Side-effect & safety grid
- No human trials; safety and pharmacokinetics in humans unknown.
- Not FDA-approved.
- Investigational; not FDA-approved.
- Injection-site reactions are common in trials.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
FOXO4-DRI vs SS-31 (Elamipretide) — Key differences
- Class: FOXO4-DRI is classified as Longevity · Senolytic, while SS-31 (Elamipretide) is Mitochondrial.
- Primary research focus: FOXO4-DRI — senescent cell clearance; SS-31 (Elamipretide) — heart failure with preserved ejection fraction.
- Tag: Longevity · Senolytic vs Mitochondrial.